Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD37Q5)

Drug Name

SEL24 Drug Info

Synonyms

MEN1703

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 1/2	[1]

Cross-matching ID

PubChem CID: 154731776
TTD Drug ID: DMD37Q5

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Serine/threonine-protein kinase pim (PIM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
INCB53914	DMKMSP2	Advanced malignancy	2A00-2F9Z	Phase 1/2	[3]
PIM447	DMU26OE	Myelofibrosis	2A20.2	Phase 1	[3]
TP-3654	DMBQ6XY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
------------------------------------------------------------------------------------

Drug(s) Targeting Fms-like tyrosine kinase 3 (FLT-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[5]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[6]
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[7]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[8]
Gilteritinib	DMTI0ZO	Acute myeloid leukaemia	2A60	Approved	[9]
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[10]
Pacritinib	DM1T6ZN	Myelofibrosis	2A20.2	Approved	[5]
Quizartinib	DM8Y4JS	Acute myeloid leukaemia	2A60	Approved	[3]
Lestaurtinib	DMQ2AIJ	Acute myeloid leukaemia	2A60	Approved (orphan drug)	[11]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fms-like tyrosine kinase 3 (FLT-3)	TTGJCWZ	FLT3_HUMAN	Inhibitor	[2]
Serine/threonine-protein kinase pim (PIM)	TTA7WGU	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03008187) SEL24/MEN1703 in Patients With Acute Myeloid Leukemia. U.S. National Institutes of Health.
2	A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget. 2018 Mar 30;9(24):16917-16931.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
8	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
9	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
10	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
11	Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.
12	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.